[{"id":"2b61255d-6755-44e9-9c55-2f4aef8d1886","acronym":"","url":"https://clinicaltrials.gov/study/NCT05472506","created_at":"2022-07-25T20:54:29.805Z","updated_at":"2025-02-25T14:17:08.068Z","phase":"Phase 1","brief_title":"Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer","source_id_and_acronym":"NCT05472506","lead_sponsor":"Ikena Oncology","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • IK-175"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2024-03-15"}]